Charles River Laboratories consensus in focus, shares tracked ahead of next earnings

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 18:42.

Charles River Laboratories International (US1591881009) remains a closely watched name on the NYSE as investors digest the latest earnings beat and updated analyst estimates for 2026. Consensus models now frame expectations for the next earnings date and margin path in the contract research sector.

What recent numbers show

Charles River Laboratories reported first-quarter 2026 earnings on May 7, 2026, posting earnings per share of 2.06 US dollars versus a consensus of 1.96 US dollars, according to data compiled by MarketBeat. This roughly 5 percent beat on EPS underpins several refreshed models for the year. MarketBeat earnings summary for CRL

Revenue and margin details from that quarter have set the base for updated forecasts in the contract research and life sciences tools peer group, including global players such as IQVIA and Labcorp. Analysts monitor how Charles River balances demand from large pharma clients with cost discipline in a still-robust outsourcing trend.

Analyst views and valuation

Several research houses track Charles River Laboratories with a focus on valuation versus growth, placing the stock within the broader US healthcare and S&P 500 context. Recent commentary highlights that the company benefits from structural demand for preclinical and early-stage drug development services. Simply Wall St analysis on CRL

In the same sector, contract research peers like IQVIA on the NYSE and Charles River Associates on the NASDAQ offer investors additional benchmarks for margins, capital allocation, and leverage. For Charles River, analyst discussions often center on balancing investment in capacity and innovation with maintaining returns on capital.

How Charles River earns its money

Charles River Laboratories generates revenue primarily from preclinical and early-stage contract research services that support pharmaceutical, biotechnology, and academic clients worldwide. Key offerings include research models, safety assessment, and discovery services that help accelerate drug development decisions.

Where the shares trade today

The Charles River Laboratories shares (US1591881009) most recently traded on the NYSE at 184.62 US dollars on 2026-06-22, 09:53 Eastern Time, based on exchange data.

This article is for informational purposes only and does not constitute investment advice, investment recommendation, or an offer or solicitation to buy or sell any financial instrument. Investors should conduct their own research and consider consulting a qualified financial advisor before making investment decisions.